'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study

(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…

Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120096

Author :

Publish date : 2026-02-27 22:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study

More Parents Say ‘No’ to Vitamin K Shots for Newborns

I woke up from an operation in agony and the pain never went away

Related Posts

Discussing Anti-Amyloid Therapies in Alzheimer’s Disease

Supreme Court Restores Access to Abortion Pill by Mail

What to Know About Hantavirus, the Illness Suspected in a Cruise Ship Outbreak

No Survival Benefit With Mastectomy in Younger, High-Risk Breast Cancer

Changes in Gut Microbiome an Early Sign of Parkinson’s?

When to Call Neurosurgery for Traumatic Brain Injury

Discussing Anti-Amyloid Therapies in Alzheimer’s Disease

Supreme Court Restores Access to Abortion Pill by Mail

What to Know About Hantavirus, the Illness Suspected in a Cruise Ship Outbreak

No Survival Benefit With Mastectomy in Younger, High-Risk Breast Cancer

Changes in Gut Microbiome an Early Sign of Parkinson’s?

When to Call Neurosurgery for Traumatic Brain Injury

Giuliani Hospitalized; 3 Dead in Suspected Outbreak; Abortion Back at SCOTUS?

300-year-old experiment could become world’s best dark matter detector

Categories

Archives